Semaglutide and tirzepatide come up often in conversations about medical weight loss. Both affect pathways involved in appetite and blood sugar regula…
Semaglutide and tirzepatide come up often in conversations about medical weight loss. Both affect pathways involved in appetite and blood sugar regulation, but they are different medications.
Understanding those differences can help you have a more informed conversation with your healthcare provider. The right choice depends on your medical history, the specific product being considered, and how treatment fits into your ongoing care.
How do they work?
Semaglutide activates GLP-1 receptors. This pathway helps regulate appetite, food intake, and blood sugar. Semaglutide can help people feel less hungry and eat less.
Tirzepatide activates both GLP-1 and GIP receptors. These two hormone pathways play roles in blood sugar regulation and appetite. Its dual action distinguishes it from semaglutide, but does not automatically make it the right option for every person.
Both have FDA-approved products used for weight management: Wegovy contains semaglutide, while Zepbound contains tirzepatide. Approval applies to a specific product and its labeled uses—not every preparation containing the same active ingredient. Wegovy prescribing information, FDA information on Zepbound.
How should you compare weight-loss results?
Before comparing percentages from an advertisement, look at what was actually studied.
Which product and dose did participants receive? How long did treatment last? Did participants have diabetes? What nutrition and activity support was included?
Those details matter. A result from a study of one formulation cannot simply be applied to a different formulation or dosing schedule. Ask your provider which evidence applies to the exact treatment they are recommending—and what realistic progress might look like for you.
What about side effects?
Both medications can cause digestive side effects, including nausea, vomiting, diarrhea, constipation, and abdominal discomfort. Your provider should explain how to manage common symptoms and when to seek medical attention.
Their prescribing information also includes serious warnings and restrictions. For example, Wegovy and Zepbound should not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Discuss your medical history, pregnancy plans, and all medications and supplements before starting treatment. This is not a complete list of safety considerations. Wegovy safety information, Zepbound safety overview.
Are compounded versions the same?
Compounded semaglutide and tirzepatide are not FDA-approved medications. FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed.
The FDA states that compounded drugs should only be used when a patient’s medical needs cannot be met by an FDA-approved drug. If compounding is discussed, ask why it is being considered for you, which pharmacy would dispense it, and what evidence supports the proposed formulation.
An injection and a dissolving tablet should not be assumed to have the same absorption, effectiveness, or dosing simply because they list the same active ingredient. FDA guidance on unapproved GLP-1 medications.
What should you ask before choosing?
Bring these questions to your consultation:
Why are you recommending this specific medication and formulation?
How does my medical history affect the decision?
What does the total price include?
How will we monitor side effects and progress?
What happens if treatment is ineffective or difficult to tolerate?
You do not need to choose a medication before speaking with a provider. Start with your goals and questions, then work toward a plan you understand.
Explore weight-loss care through Vitl.Life. Vitl.Life connects patients with independent licensed healthcare providers who determine whether prescription treatment is medically appropriate.
This article is for educational purposes and does not replace individualized medical advice. Prescription treatment requires evaluation by a licensed healthcare provider. Individual results vary.